SUBSTITUTED 3-FLUOROBENZENEPROPANOATE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF

Abstract

A substituted 3-fluorobenzenepropanoate compound represented by formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate (such as a hydrate) thereof, a clathrate thereof, a racemate thereof, a co-crystal thereof, an isotopic label thereof, or a nitrogen oxide thereof, as well as pharmaceutical compositions and uses thereof. The compound has significantly elevated drug activity, and can effectively treat and/or prevent inflammation, pain, fever, cancer, or senile dementia.

Claims

1-9. (canceled)

10. A compound represented by formula (I), or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof (such as a hydrate), or an inclusion compound thereof, or a racemate thereof, or a co-crystal thereof, or an isotopically labelled compound thereof, or a nitrogen oxide thereof, ##STR00109## wherein X is alkylene; P is ##STR00110## in formula (a), Y is a single bond, O, S, or NH; W is a single bond or alkylene; R.sub.1 and R.sub.2 are the same or different and are each independently selected from H, optionally substituted alkyl, and optionally substituted aryl, or R.sub.1 and R.sub.2 are linked to each other and jointly form, together with the nitrogen atoms to which they are linked, optionally substituted aliphatic heterocyclyl or ##STR00111## there are one or two R.sub.5, each independently selected from H and alkyl; in formula (c), a dashed line indicates a single bond or null; in formula (b), A is a single bond, O(CO) or O(CO)-alkylene; R.sub.3 is an optional group; there is one or more R.sub.3, if present, and each independently alkyl, hydroxy, carboxy, hydroxy-substituted alkyl, alkoxy, or N(R.sub.6)(R.sub.7), and R.sub.6 and R.sub.7 are the same or different and are each independently alkyl; R.sub.4 is selected from H, alkyl, and alkylacyl; or R.sub.3 and OR.sub.4 are linked to each other to form an aliphatic heterocyclic ring; the optionally substituted refers to being unsubstituted or substituted with one or more substituents, wherein the substituents in the optionally substituted alkyl, optionally substituted aryl, and optionally substituted aliphatic heterocyclyl are each independently selected from hydroxy, amino, carboxy, halogen, nitro, cyano, alkyl, alkylthio, alkylacyl, and hydroxy-substituted aryl.

11. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10, wherein X is alkylene; P is ##STR00112## in formula (a), Y is a single bond, O, S, or NH; W is a single bond; R.sub.1 and R.sub.2 are the same or different and are each independently selected from H, optionally substituted alkyl, and optionally substituted aryl, or R.sub.1 and R.sub.2 are linked to each other and jointly form, together with the nitrogen atoms to which they are linked, optionally substituted aliphatic heterocyclyl; in formula (b), A is a single bond, O(CO) or O(CO)-alkylene; R.sub.3 is an optional group; there is one or more R.sub.3, if present, and each independently alkyl, hydroxy, carboxy, hydroxy-substituted alkyl, alkoxy, or N(R.sub.6)(R.sub.7), and R.sub.6 and R.sub.7 are the same or different and are each independently alkyl; R.sub.4 is selected from H, alkyl, and alkylacyl; or R.sub.3 and OR.sub.4 are linked to each other to form an aliphatic heterocyclic ring; the optionally substituted refers to being unsubstituted or substituted with one or more substituents, wherein the substituents in the optionally substituted alkyl, optionally substituted aryl, and optionally substituted aliphatic heterocyclyl are each independently selected from hydroxy, amino, carboxy, halogen, nitro, cyano, alkyl, alkylthio, alkylacyl, and hydroxy-substituted aryl.

12. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10, wherein the alkyl moieties in the alkyl, alkylacyl, hydroxy-substituted alkyl, alkoxy, and alkylthio are each independently C.sub.1-20 linear or branched alkyl, optionally C.sub.1-17 linear or branched alkyl, optionally C.sub.1-10 linear or branched alkyl, optionally C.sub.1-7 linear or branched alkyl, optionally methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl, heptyl, n-octyl, n-nonyl, n-decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, or hexadecyl; optionally, the alkylene is C.sub.1-20 linear or branched alkylene, optionally C.sub.1-17 linear or branched alkylene, optionally C.sub.1-10 linear or branched alkylene, optionally C.sub.1-8 linear or branched alkylene, optionally C.sub.1-6 linear or branched alkylene, optionally C.sub.1-3 linear or branched alkylene, optionally methylene, ethylene, isoethylidene, n-propylene, isopropylene, n-butylidene, isobutylidene, tert-butylidene, sec-butylidene, n-pentylidene, isopentylidene, neopentylidene, tert-pentylidene, n-hexylidene, isohexylidene, heptylidene, n-octylidene, n-nonylidene, or n-decylidene; optionally, the aliphatic heterocyclic ring in the aliphatic heterocyclic ring or aliphatic heterocyclyl is a C.sub.3-8 (preferably C.sub.4-6) aliphatic heterocyclic ring containing 1 to 3 heteroatoms selected from O, N, and S on the ring, optionally dioxolane, aziridinyl, azetidinyl, tetrahydropyrrolyl, morpholinyl, piperidinyl, or piperazinyl; optionally, the aryl or hydroxy-substituted aryl is a 6- to 10-membered monocyclic or bicyclic fused aromatic ring group; optionally phenyl or naphthyl; optionally, the present disclosure relates to the compounds as described above and any appended definitions, wherein a 3-fluorobenzenepropanoate moiety is in an S configuration or an R configuration.

13. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 11, wherein the alkyl moieties in the alkyl, alkylacyl, hydroxy-substituted alkyl, alkoxy, and alkylthio are each independently C1-20 linear or branched alkyl, optionally C1-17 linear or branched alkyl, optionally C1-10 linear or branched alkyl, optionally C1-7 linear or branched alkyl, optionally methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl, heptyl, n-octyl, n-nonyl, n-decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, or hexadecyl; optionally, the alkylene is C1-20 linear or branched alkylene, optionally C1-17 linear or branched alkylene, optionally C1-10 linear or branched alkylene, optionally C1-8 linear or branched alkylene, optionally C1-6 linear or branched alkylene, optionally C1-3 linear or branched alkylene, optionally methylene, ethylene, isoethylidene, n-propylene, isopropylene, n-butylidene, isobutylidene, tert-butylidene, sec-butylidene, n-pentylidene, isopentylidene, neopentylidene, tert-pentylidene, n-hexylidene, isohexylidene, heptylidene, n-octylidene, n-nonylidene, or n-decylidene; optionally, the aliphatic heterocyclic ring in the aliphatic heterocyclic ring or aliphatic heterocyclyl is a C3-8 (preferably C4-6) aliphatic heterocyclic ring containing 1 to 3 heteroatoms selected from O, N, and S on the ring, optionally dioxolane, aziridinyl, azetidinyl, tetrahydropyrrolyl, morpholinyl, piperidinyl, or piperazinyl; optionally, the aryl or hydroxy-substituted aryl is a 6- to 10-membered monocyclic or bicyclic fused aromatic ring group; optionally phenyl or naphthyl; optionally, the present disclosure relates to the compounds as described above and any appended definitions, wherein a 3-fluorobenzenepropanoate moiety is in an S configuration or an R configuration.

14. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10, wherein R.sub.1 and R.sub.2 are the same or different and are each independently selected from H, n-propyl, isopropyl, ##STR00113## or R.sub.1 and R.sub.2 are linked to each other and jointly form, together with the nitrogen atoms to which they are linked, the following group: heterocyclopropan-1-yl, azetidin-1-yl, tetrahydropyrrol-1-yl, morpholin-1-yl, piperidin-1-yl, or piperazin-1-yl, ##STR00114## optionally, when R.sub.3 and OR.sub.4 are linked to each other to form an aliphatic heterocyclic ring, the aliphatic heterocyclic ring is dioxolane.

15. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 11, wherein R.sub.1 and R.sub.2 are the same or different and are each independently selected from H, n-propyl, isopropyl, ##STR00115## or R.sub.1 and R.sub.2 are linked to each other and jointly form, together with the nitrogen atoms to which they are linked, the following group: heterocyclopropan-1-yl, azetidin-1-yl, tetrahydropyrrol-1-yl, morpholin-1-yl, piperidin-1-yl, or piperazin-1-yl, ##STR00116## optionally, when R.sub.3 and OR.sub.4 are linked to each other to form an aliphatic heterocyclic ring, the aliphatic heterocyclic ring is dioxolane.

16. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10, wherein the pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt, preferably selected from hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, tartaric acid, formic acid, acetic acid, salicylic acid, citric acid, succinic acid, fumaric acid, or benzoic acid.

17. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 11, wherein the pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt, preferably selected from hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, tartaric acid, formic acid, acetic acid, salicylic acid, citric acid, succinic acid, fumaric acid, or benzoic acid.

18. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10, which is selected from the following compounds, or optical isomers thereof, or solvates thereof, or inclusion compounds thereof, or racemates thereof, or co-crystals thereof, or isotopically labelled compounds thereof, or nitrogen oxides thereof: ##STR00117## ##STR00118## ##STR00119## ##STR00120## ##STR00121## ##STR00122## ##STR00123## ##STR00124## ##STR00125## ##STR00126## ##STR00127## ##STR00128## ##STR00129## ##STR00130##

19. The compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 11, which is selected from the following compounds, or optical isomers thereof, or solvates thereof, or inclusion compounds thereof, or racemates thereof, or co-crystals thereof, or isotopically labelled compounds thereof, or nitrogen oxides thereof: ##STR00131## ##STR00132## ##STR00133## ##STR00134## ##STR00135## ##STR00136## ##STR00137## ##STR00138## ##STR00139##

20. A preparation method for the compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10, wherein in formula (I), when P is ##STR00140## the preparation method comprises a step of preparing formula (II) from a compound of formula (A) and a compound of formula (B) by method A: method A: preparing formula (II) by subjecting formula (A) and formula (B) to a substitution reaction; ##STR00141## wherein formula (A) is an R configuration, an S configuration or a racemate; in formula (B) and formula (II), X, Y, W, R.sub.1 and R.sub.2 are as described in formula (I); in formula (B), D is selected from Cl, Br, I, OTs, and OMs; each Y is O, S, or NH, wherein R.sub.1 and R.sub.2 are as described in formula (I); optionally, formula (II) is prepared by subjecting formula (A) and formula (B) to a substitution reaction in a suitable solvent at a suitable temperature under catalysis of a base; optionally, in the method A, the base used for the substitution reaction is one or more selected from pyridine or triethylamine or N,N-diisopropylethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene or potassium carbonate or cesium carbonate or sodium hydride or lithium bis(trimethylsilyl)amide; optionally, the solvent for the substitution reaction is one or more selected from DMF or DMAC or dimethyl sulfoxide or NMP or DCM or tetrahydrofuran or acetonitrile or ethyl acetate or isopropyl acetate or dioxane or acetone; optionally, the temperature for the substitution reaction is 0 C. to 100 C.; optionally, formula (B) can be prepared by, but not limited to, one of the following steps 1 to 3: step 1: ##STR00142## at room temperature, a saturated sodium bicarbonate solution and tetrabutylammonium hydrogen sulfate at a catalytic amount are added to a solution of an acid in dichloromethane that is being vigorously stirred, and then chloromethyl chlorosulfonate is added; after the reaction is completed, the reaction solution is layered, and the organic phases are collected, dried over anhydrous sodium sulfate, evaporated to dryness via rotary evaporation under reduced pressure, and purified by column chromatography to yield the compound of formula (B); and/or step 2: ##STR00143## a chlorination reagent and sodium iodide (or potassium iodide) are refluxed in acetonitrile (or acetone); after the reaction is completed, the solvent is removed under reduced pressure, an organic solvent and water are added; the reaction solution is layered, and the organic phases are collected and dried over anhydrous sodium sulfate; and the solvent is removed under reduced pressure to yield a corresponding iodinated compound of formula (B); optionally, when W is absent, formula (B) is synthesized by step 3; or step 3: ##STR00144## at 0 C., a corresponding secondary amine is added to a solution of chloromethyl chloroformate in dichloromethane; after the reaction is completed, the reaction solution is filtered, and the organic phases are washed with 1N hydrochloric acid and dried over anhydrous sodium sulfate; and the solvent is removed under reduced pressure to yield the compound of formula (B); or when W is a single bond, the preparation method comprises preparing formula (II) from formula (A), formula (C) and formula (M) by method B; method B: {circle around (1)} preparing formula (D) by subjecting formula (A) and formula (C) to a condensation reaction; {circle around (2)} preparing formula (E) by de-protecting formula (D); and preparing formula (II) by condensing formula (E) with formula (M); ##STR00145## wherein Y is a single bond, and X, R.sub.1 and R.sub.2 are as described in formula (I); formula (A) is an R configuration, an S configuration or a racemate; in formula (C), Rz is methyl, ethyl, tert-butyl, benzyl, or p-methoxybenzyl; and E is OH; or when P is ##STR00146## the preparation method comprises preparing formula (III) from a compound of formula (A) and a compound of formula (F) by method C; method C: preparing formula (III) by subjecting formula (A) and formula (F) to a condensation reaction; ##STR00147## wherein in formula (F), A is a single bond, and X, R.sub.3 and R.sub.4 are as described in formula (I); in formula (F), Z is selected from OH, NH.sub.2, SH, and NH; optionally, in the method B and method C, a condensing agent for the condensation reaction is one or more selected from DCC, DIC, EDCI, HATU, HBTU, CDI, HCTU, TBTU, TSTU, TNTU, HAPyU, HBPyU, BOP, PyBOP, PyAOP, DPPCI, DECP, DPPA, MPTA, or BOPCl, optionally a solvent for the condensation reaction is one or more selected from dichloromethane, dimethyl sulfoxide, N,N-dimethylformamide, hexamethylphosphoric triamide, or acetonitrile; optionally, the temperature for the condensation reaction is 0 C. to 100 C.; or the preparation method comprises preparing a compound of formula (III) from formula (A) by method D: method D: ##STR00148## wherein in formula (F), A is a single bond, and X, R.sub.3, R.sub.4 and Z are as described above; or the preparation method comprises preparing a compound of formula (III) from formula (A) and formula (H) by method E: method E: ##STR00149## wherein in formula (H), A is O(CO); G is Cl, Br, I, OMs, or OTs; and X, R.sub.3 and R.sub.4 are as described in formula (I).

21. A pharmaceutical composition, comprising the compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10, and a pharmaceutically acceptable excipient, optionally, the pharmaceutically acceptable excipient is selected from fillers, disintegrants, lubricants, glidants, effervescent agents, flavoring agents, preservatives, solubilizers, cosolvents, antioxidants, anti-photolysis agents, pH regulators, emulsifiers, antibacterial preservatives, topical analgesics, complexing agents, non-aqueous solvents, coating materials or other vehicles; optionally, as the pharmaceutically acceptable excipient, the fillers comprise a composition of one or more of lactose, mannitol, and calcium carbonate; the binders comprise a composition of one or more of sucrose, starch, povidone, and sodium carboxymethyl cellulose; the disintegrants comprises a composition of one or more of starch, cross-linked povidone, cross-linked sodium carboxymethyl cellulose, and effervescent disintegrants; the non-aqueous solvents comprise a composition of one or more of soybean oil, castor oil, and peanut oil; the solubilizers comprise a composition of one or more of Tween 80, Tween 60, and poloxamer 68; the cosolvents comprise a composition of one or more of sodium benzoate, sodium salicylate, and sodium p-aminobenzoate; optionally, a mode of administration of the pharmaceutical composition comprises oral administration (e.g., oral cavity), sublingual administration, parenteral administration (e.g., intramuscular, intravenous or subcutaneous administration), rectal administration (e.g., by suppositories or lotions), transdermal administration (skin electroporation, transdermal preparations, etc., such as creams, gels, paints, and transdermal patches) or inhalation administration (e.g., aerosols); optionally, the pharmaceutical composition is administered in a single unit dose form or in an ad libitum single dose under continuous treatment; optionally, the pharmaceutical composition may further be in the form of an oil emulsion or dispersion in combination with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for use in subcutaneous or intramuscular administration; optionally, the pharmaceutical composition may be prepared into a solid oral formulation, a liquid oral formulation, an injection, or a transdermal formulation; optionally, the solid and liquid oral formulations comprise: tablets, dispersible tablets, sugar-coated tablets, granules, dry powders, capsules, syrups, and solutions; optionally, the injection comprises: small injections, large volume parenteral, and lyophilized powder injections; optionally, the transdermal formulation comprises: ointments, plasters, liniments, aerosols, traditional pastes, adhesive dispersion patches, peripheral adhesive skeleton patches, reservoir patches, and cataplasms.

22. A pharmaceutical composition, comprising the compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 11, and a pharmaceutically acceptable excipient, optionally, the pharmaceutically acceptable excipient is selected from fillers, disintegrants, lubricants, glidants, effervescent agents, flavoring agents, preservatives, solubilizers, cosolvents, antioxidants, anti-photolysis agents, pH regulators, emulsifiers, antibacterial preservatives, topical analgesics, complexing agents, non-aqueous solvents, coating materials or other vehicles; optionally, as the pharmaceutically acceptable excipient, the fillers comprise a composition of one or more of lactose, mannitol, and calcium carbonate; the binders comprise a composition of one or more of sucrose, starch, povidone, and sodium carboxymethyl cellulose; the disintegrants comprises a composition of one or more of starch, cross-linked povidone, cross-linked sodium carboxymethyl cellulose, and effervescent disintegrants; the non-aqueous solvents comprise a composition of one or more of soybean oil, castor oil, and peanut oil; the solubilizers comprise a composition of one or more of Tween 80, Tween 60, and poloxamer 68; the cosolvents comprise a composition of one or more of sodium benzoate, sodium salicylate, and sodium p-aminobenzoate; optionally, a mode of administration of the pharmaceutical composition comprises oral administration (e.g., oral cavity), sublingual administration, parenteral administration (e.g., intramuscular, intravenous or subcutaneous administration), rectal administration (e.g., by suppositories or lotions), transdermal administration (skin electroporation, transdermal preparations, etc., such as creams, gels, paints, and transdermal patches) or inhalation administration (e.g., aerosols); optionally, the pharmaceutical composition is administered in a single unit dose form or in an ad libitum single dose under continuous treatment; optionally, the pharmaceutical composition may further be in the form of an oil emulsion or dispersion in combination with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for use in subcutaneous or intramuscular administration; optionally, the pharmaceutical composition may be prepared into a solid oral formulation, a liquid oral formulation, an injection, or a transdermal formulation; optionally, the solid and liquid oral formulations comprise: tablets, dispersible tablets, sugar-coated tablets, granules, dry powders, capsules, syrups, and solutions; optionally, the injection comprises: small injections, large volume parenteral, and lyophilized powder injections; optionally, the transdermal formulation comprises: ointments, plasters, liniments, aerosols, traditional pastes, adhesive dispersion patches, peripheral adhesive skeleton patches, reservoir patches, and cataplasms.

23. A method for preventing and/or treating inflammation, pain, fever, cancer, Alzheimer's disease, including giving an effect amount of the compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10 to the subject in deed, optionally, the inflammation is selected from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, scapulohumeral periarthritis, myotenositis and tenosynovitis, peritendinitis, lateral epicondylitis (tennis elbow), postoperative anti-inflammation, and swelling and inflammation caused by injury; optionally, the pain is selected from mild to moderate pain, pain after trauma or strain, dysmenorrhea and postoperative pain, toothache and cancer pain, acute pain in adults, etc.; optionally, the fever comprises fever caused by common cold or influenza; optionally, the cancer is selected from gastric cancer, esophageal cancer, multiple myeloma, brain glioma, and lung cancer; optionally, cells of the cancer comprise human esophageal carcinoma cell Eca-109, human multiple myeloma cell MM.1S, human gastric carcinoma cell NUGC-4, human brain astrocyte U87, human glioma cell U251, and large cell lung carcinoma cell H460.

24. A method for preventing and/or treating inflammation, pain, fever, cancer, Alzheimer's disease, including giving an effect amount of the compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 11 to the subject in deed, optionally, the inflammation is selected from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, scapulohumeral periarthritis, myotenositis and tenosynovitis, peritendinitis, lateral epicondylitis (tennis elbow), postoperative anti-inflammation, and swelling and inflammation caused by injury; optionally, the pain is selected from mild to moderate pain, pain after trauma or strain, dysmenorrhea and postoperative pain, toothache and cancer pain, acute pain in adults, etc.; optionally, the fever comprises fever caused by common cold or influenza; optionally, the cancer is selected from gastric cancer, esophageal cancer, multiple myeloma, brain glioma, and lung cancer; optionally, cells of the cancer comprise human esophageal carcinoma cell Eca-109, human multiple myeloma cell MM.1S, human gastric carcinoma cell NUGC-4, human brain astrocyte U87, human glioma cell U251, and large cell lung carcinoma cell H460.

25. A method for preventing and/or treating inflammation, pain, fever, cancer or Alzheimer's disease, including giving an effect amount of the compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 10 in combination with an additional one or more second active compounds to the subject in deed; optionally, the inflammation is selected from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, scapulohumeral periarthritis, myotenositis and tenosynovitis, peritendinitis, lateral epicondylitis (tennis elbow), postoperative anti-inflammation, and swelling and inflammation caused by injury; optionally, the pain is selected from mild to moderate pain, pain after trauma or strain, such as dysmenorrhea and postoperative pain, toothache and cancer pain, acute pain in adults, etc.; optionally, the fever comprises fever caused by common cold or influenza; optionally, the cancer is selected from gastric cancer, esophageal cancer, multiple myeloma, brain glioma, and lung cancer; optionally, cells of the cancer comprise human esophageal carcinoma cell Eca-109, human multiple myeloma cell MM.1S, human gastric carcinoma cell NUGC-4, human brain astrocyte U87, human glioma cell U251, or large cell lung carcinoma cell H460; optionally, examples of the additional one or more second active compounds as active drugs are one or more selected from the following substances: sufentanil, dexmedetomidine, formoterol, isoproterenol, salbutamol, bambuterol, procaterol, fenoterol, arformoterol, tulobuterol, clenbuterol, salmeterol, salmeterol casone, terbutaline, orciprenaline, and chlorprenaline.

26. A method for preventing and/or treating inflammation, pain, fever, cancer or Alzheimer's disease, including giving an effect amount of the compound represented by formula (I), or the optical isomer thereof, or the pharmaceutically acceptable salt thereof, or the solvate thereof (such as a hydrate), or the inclusion compound thereof, or the racemate thereof, or the co-crystal thereof, or the isotopically labelled compound thereof, or the nitrogen oxide thereof according to claim 11 in combination with an additional one or more second active compounds to the subject in deed; optionally, the inflammation is selected from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, scapulohumeral periarthritis, myotenositis and tenosynovitis, peritendinitis, lateral epicondylitis (tennis elbow), postoperative anti-inflammation, and swelling and inflammation caused by injury; optionally, the pain is selected from mild to moderate pain, pain after trauma or strain, such as dysmenorrhea and postoperative pain, toothache and cancer pain, acute pain in adults, etc.; optionally, the fever comprises fever caused by common cold or influenza; optionally, the cancer is selected from gastric cancer, esophageal cancer, multiple myeloma, brain glioma, and lung cancer; optionally, cells of the cancer comprise human esophageal carcinoma cell Eca-109, human multiple myeloma cell MM.1S, human gastric carcinoma cell NUGC-4, human brain astrocyte U87, human glioma cell U251, or large cell lung carcinoma cell H460; optionally, examples of the additional one or more second active compounds as active drugs are one or more selected from the following substances: sufentanil, dexmedetomidine, formoterol, isoproterenol, salbutamol, bambuterol, procaterol, fenoterol, arformoterol, tulobuterol, clenbuterol, salmeterol, salmeterol casone, terbutaline, orciprenaline, and chlorprenaline.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0131] FIG. 1 is a diagram showing changes in body weight of rats in each of groups during administration in Test Example 4 (n=8, MeanSD).

[0132] FIG. 2 is a diagram showing the arthritis scores of rats with CIA after 14-day intervention with each of test drugs in Test Example 4 (n=8, MeanSD).

[0133] FIG. 3 is a diagram showing the toe volume changes in the left hind limbs of rats with CIA after 14-day intervention with each of test drugs in Test Example 4 (n=8, MeanSD).

[0134] FIG. 4 shows the mechanical withdrawal thresholds of the left lower limbs of rats in each of groups after 13-day intervention with each of test drugs in Test Example 4 (MeanSD).

DETAILED DESCRIPTION

[0135] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by a person skilled in the art. If there are multiple definitions for a term used herein, the definition defined here will prevail unless otherwise stated.

[0136] The examples of the present disclosure will be described in detail below, but the examples provided herein are not intended to limit the present disclosure in any way.

EXAMPLES

General Synthetic Method 1:

[0137] Method B was adopted for synthesis.

Step 1:

[0138] Formula (A) (1.0 eq.), tert-butyl 2-glycolate (1.1 eq.), EDCI (1.5 eq.), and DMAP (0.1 eq.) were added to 5 mL of DMF, and stirred at room temperature for 12 h. Ethyl acetate was added. Thereafter, the organic phases were washed with a saturated aqueous ammonium chloride solution, water, and a saturated aqueous sodium chloride solution in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was evaporated to dryness under reduced pressure. The product was dissolved into DCM, and trifluoroacetic acid (2 mL) was added, stirred for 4 h, and then concentrated under reduced pressure to yield a white solid.

Step 2:

[0139] The above product (1.0 eq.), formula (M) (1.1 to 2 eq.), HATU (1.2 to 1.5 eq.), and DIPEA (5.0 eq.) were added to 5 mL of DMF, and stirred at room temperature for 4 h. After the reaction was completed, ethyl acetate was added. Thereafter, the organic phases were washed with a saturated aqueous ammonium chloride solution, water, and a saturated aqueous sodium chloride solution in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to yield the product.

Example 1: Preparation of Compound 1

##STR00041##

[0140] General Synthetic Method 1 was employed for preparation to yield a colorless liquid with a yield of 47.9%.

[0141] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.57-7.44 (m, 5H), 7.43-7.38 (m, 1H), 7.34-7.26 (m, 2H), 4.90-4.77 (m, 2H), 4.00 (q, J=7.2 Hz, 1H), 3.55 (t, J=4.8 Hz, 4H), 3.41 (d, J=5.0 Hz, 2H), 3.35 (s, 2H), 1.47 (d, J=7.1 Hz, 3H).

Example 2: Preparation of Compound 10

##STR00042##

[0142] General Synthetic Method 1 was employed for preparation to yield a colorless liquid with a yield of 41.3%.

[0143] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.57-7.52 (m, 2H), 7.52-7.45 (m, 3H), 7.43-7.38 (m, 1H), 7.34-7.26 (m, 2H), 4.90 (d, J=5.7 Hz, 2H), 4.00-3.94 (m, 1H), 3.67-3.58 (m, 1H), 3.52 (q, J=5.3 Hz, 2H), 3.46 (q, J=5.9 Hz, 2H), 3.33 (s, 4H), 3.18-3.10 (m, 1H), 1.46 (d, J=7.1 Hz, 3H).

Example 3: Preparation of Compound 11

##STR00043##

[0144] General Synthetic Method 1 was employed for preparation to yield a colorless liquid with a yield of 52.6%.

[0145] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.56-7.45 (m, 5H), 7.43-7.38 (m, 1H), 7.35-7.26 (m, 2H), 4.94-4.80 (m, 2H), 4.00 (q, J=7.1 Hz, 1H), 3.42 (m, 8H), 2.01 (s, 3H), 1.47 (d, J=7.1 Hz, 3H).

Example 4: Preparation of Compound 12

##STR00044##

[0146] General Synthetic Method 1 was employed for preparation to yield a colorless liquid with a yield of 59.6%.

[0147] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.57-7.45 (m, 5H), 7.43-7.37 (m, 1H), 7.34-7.23 (m, 2H), 4.61-4.48 (m, 2H), 4.09 (td, J=7.8, 3.5 Hz, 2H), 3.99 (q, J=7.1 Hz, 1H), 3.87 (t, J=7.7 Hz, 2H), 2.21 (p, J=7.6 Hz, 2H), 1.45 (d, J=7.1 Hz, 3H).

General Synthetic Method 2:

[0148] Method A was adopted for synthesis.

Step 1:

[0149] Formula (M) (1.0 eq.) or protective group (Boc, tert-butyl)-protected formula (M) (1.0 eq.) was dissolved into DCM. At 0 C., chloromethyl chloroformate or 1-chloroethyl chloroformate (1.1 to 1.5 eq.) and pyridine (1.6 eq.) or triethylamine (0.6 to 1.6 eq.) were added dropwise, and stirred at 78 C. to room temperature for 1 h. After the reaction was completed, DCM and water were added for extraction. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to yield a transparent colorless compound.

Step 2:

[0150] Formula (A) (1.0 eq.) was dissolved into anhydrous DMF, and potassium carbonate (1.6 to 2.0 eq.) was added. Afterwards, the above product was dissolved into DMF, and added to the reaction solution dropwise, heated to 40 C. to 50 C., and stirred for 4 h. After the reaction was completed, ethyl acetate was added. Thereafter, the organic phases were washed with a saturated aqueous ammonium chloride solution, water, and a saturated aqueous sodium chloride solution in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, then concentrated under reduced pressure, and purified by silica gel column chromatography to yield the product.

[0151] After the product was obtained from protective group-protected formula (M), it was de-protected by hydrochloric acid or trifluoroacetic acid to yield the final product.

Example 5: Preparation of Compound 2

##STR00045##

[0152] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 64.7%.

[0153] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.54 (dt, J=8.2, 1.6 Hz, 2H), 7.51-7.45 (m, 3H), 7.43-7.38 (m, 1H), 7.27-7.18 (m, 2H), 5.78-5.68 (m, 2H), 3.97 (q, J=7.1 Hz, 1H), 3.48 (d, J=14.3 Hz, 4H), 3.30 (s, 4H), 1.43 (d, J=7.1 Hz, 3H).

Example 6: Preparation of Compound 13

##STR00046##

[0154] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 50.9%.

[0155] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.56-7.44 (m, 5H), 7.43-7.37 (m, 1H), 7.25-7.18 (m, 2H), 5.74 (d, J=5.9 Hz, 1H), 5.65 (s, 1H), 3.94 (q, J=7.1 Hz, 1H), 3.13-2.99 (m, 4H), 1.42 (t, J=6.5 Hz, 5H), 1.33 (q, J=7.4 Hz, 2H), 0.73 (dt, J=20.5, 7.4 Hz, 6H).

Example 7: Preparation of Compound 14

##STR00047##

[0156] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 32.4%.

[0157] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.57-7.43 (m, 5H), 7.43-7.38 (m, 1H), 7.27-7.14 (m, 2H), 6.71 (dt, J=14.6, 5.4 Hz, 1H), 3.89 (qd, J=7.0, 2.3 Hz, 1H), 3.17-2.89 (m, 4H), 1.45 (d, J=19.0 Hz, 2H), 1.43-1.37 (m, 6H), 1.36-1.21 (m, 2H), 0.83-0.63 (m, 6H).

Example 8: Preparation of Compound 15

##STR00048##

[0158] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 56.4%.

[0159] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.54-7.44 (m, 5H), 7.43-7.37 (m, 1H), 7.28-7.19 (m, 2H), 5.78-5.68 (m, 2H), 3.97 (q, J=7.1 Hz, 1H), 3.45 (s, 4H), 3.28 (s, 4H), 1.95 (s, 3H), 1.44 (d, J=7.1 Hz, 3H).

Example 9: Preparation of Compound 16

##STR00049##

[0160] General Synthetic Method 2 was employed for preparation to yield a white solid with a yield of 44.6%.

[0161] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 8.75 (s, 1H), 7.57-7.46 (m, 4H), 7.44-7.39 (m, 1H), 7.28-7.18 (m, 2H), 5.74 (s, 2H), 3.97 (q, J=7.0 Hz, 1H), 3.54 (m, 4H), 3.09 (m, 4H), 1.44 (d, J=7.1 Hz, 3H).

[0162] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 8.75 (s, 2H), 7.56-7.38 (m, 6H), 7.26-7.20 (m, 2H), 5.75 (d, J=8.0 Hz, 2H), 3.97 (q, J=7.1 Hz, 1H), 3.58-3.51 (m, 4H), 3.09 (s, 4H), 1.44 (d, J=7.1 Hz, 3H). (R.20.6, 21.11.2023)

Example 10: Preparation of Compound 18

##STR00050##

[0163] General Synthetic Method 2 was employed for preparation to yield a white solid with a yield of 36.4%.

[0164] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 9.15 (d, J=10.8 Hz, 1H), 8.52 (d, J=11.1 Hz, 1H), 7.56-7.46 (m, 5H), 7.44-7.38 (m, 1H), 7.26-7.20 (m, 2H), 5.75 (d, J=12.7 Hz, 2H), 4.07 (m, 1H), 3.97 (q, J=7.1 Hz, 2H), 3.25 (s, 2H), 2.78 (m, 2H), 1.44 (d, J=7.1 Hz, 3H), 1.19 (d, J=6.4 Hz, 6H).

Example 11: Preparation of Compound 20

##STR00051##

[0165] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 38.3%.

[0166] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.56-7.45 (m, 5H), 7.43-7.38 (m, 1H), 7.27-7.18 (m, 2H), 5.75-5.65 (m, 2H), 4.76 (d, J=3.9 Hz, 1H), 3.96 (q, J=7.1 Hz, 1H), 3.61 (s, 3H), 3.09-2.99 (m, 2H), 1.70-1.57 (m, 2H), 1.43 (d, J=7.1 Hz, 3H), 1.24 (s, 2H).

Example 12: Preparation of Compound 21

##STR00052##

[0167] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 46.7%.

[0168] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.57-7.43 (m, 5H), 7.39 (t, J=7.2 Hz, 1H), 7.27-7.16 (m, 2H), 6.71 (dq, J=12.9, 5.4 Hz, 1H), 3.90 (q, J=7.1 Hz, 1H), 3.32-3.05 (m, 4H), 1.52 (q, J=5.6 Hz, 1H), 1.48-1.29 (m, 11H).

Example 13: Preparation of Compound 22

##STR00053##

[0169] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 42.2%.

[0170] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.60-7.44 (m, 5H), 7.43-7.37 (m, 1H), 7.28-7.15 (m, 2H), 6.71 (dq, J=10.9, 5.4 Hz, 1H), 3.91 (q, J=7.1 Hz, 1H), 3.25 (t, J=5.2 Hz, 2H), 3.17 (q, J=6.0 Hz, 2H), 1.85-1.66 (m, 4H), 1.49-1.32 (m, 6H).

Example 14: Preparation of Compound 23

##STR00054##

[0171] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 34.9%.

[0172] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 12.29 (s, 1H), 7.55-7.45 (m, 5H), 7.40 (t, J=7.3 Hz, 1H), 7.25-7.18 (m, 2H), 5.74-5.68 (m, 2H), 3.96 (q, J=7.1 Hz, 1H), 3.80 (d, J=40.6 Hz, 2H), 2.89 (s, 2H), 2.42 (s, 1H), 1.78 (d, J=13.9 Hz, 2H), 1.43 (d, J=7.1 Hz, 3H), 1.41-1.33 (m, 2H).

Example 15: Preparation of Compound 24

##STR00055##

[0173] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 46.6%.

[0174] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.54-7.45 (m, 5H), 7.41 (d, J=6.8 Hz, 1H), 7.21 (d, J=11.3 Hz, 2H), 5.75 (s, 1H), 5.67 (d, J=5.9 Hz, 1H), 3.96 (d, J=7.1 Hz, 2H), 3.68 (s, 1H), 1.43 (d, J=7.1 Hz, 3H), 1.05 (m, 12H).

[0175] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.54-7.45 (m, 5H), 7.43-7.38 (m, 1H), 7.25-7.18 (m, 2H), 5.75 (d, J=5.9 Hz, 1H), 5.67 (d, J=5.9 Hz, 1H), 3.96 (q, J=7.1 Hz, 1H), 3.89 (s, 1H), 3.68 (s, 1H), 1.43 (d, J=7.1 Hz, 3H), 1.05 (d, J=18.9 Hz, 12H). (R.20.6, 21.11.2023)

Example 16: Preparation of Compound 25

##STR00056##

[0176] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 43.6%.

[0177] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.56-7.45 (m, 5H), 7.43-7.38 (m, 1H), 7.26-7.19 (m, 2H), 5.72-5.67 (m, 2H), 4.75 (td, J=5.4, 3.4 Hz, 2H), 3.96 (q, J=7.1 Hz, 1H), 3.46 (q, J=6.0 Hz, 2H), 3.39 (q, J=6.0 Hz, 2H), 3.25 (m, 4H), 1.43 (d, J=7.1 Hz, 3H).

Example 17: Preparation of Compound 3

##STR00057##

[0178] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 42.1%.

[0179] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.55-7.51 (m, 2H), 7.51-7.45 (m, 3H), 7.44-7.38 (m, 1H), 7.28-7.18 (m, 2H), 5.75 (t, J=4.8 Hz, 1H), 5.69 (d, J=5.9 Hz, 1H), 3.96 (q, J=7.1 Hz, 1H), 3.77 (d, J=13.4 Hz, 1H), 3.64 (d, J=13.1 Hz, 1H), 3.41-3.34 (m, 1H), 3.26 (s, 1H), 2.49-2.34 (m, 2H), 1.44 (d, J=7.1 Hz, 3H), 1.02 (d, J=6.6 Hz, 6H).

[0180] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.55-7.51 (m, 2H), 7.51-7.45 (m, 3H), 7.44-7.38 (m, 1H), 7.25-7.21 (m, 2H), 5.74 (d, J=4.8 Hz, 1H), 5.69 (d, J=5.9 Hz, 1H), 3.96 (q, J=7.1 Hz, 1H), 3.77 (d, J=13.4 Hz, 1H), 3.64 (d, J=13.1 Hz, 1H), 3.41-3.34 (m, 1H), 3.26 (s, 1H), 2.49-2.34 (m, 2H), 1.44 (d, J=7.1 Hz, 3H), 1.02 (d, J=6.6 Hz, 6H). (R.20.6, 21.11.2023)

Example 18: Preparation of Compound 4

##STR00058##

[0181] General Synthetic Method 2 was employed for preparation to yield a white solid with a yield of 45.2%.

[0182] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 9.89 (s, 1H), 9.18 (s, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.47 (q, J=8.1 Hz, 4H), 7.41-7.35 (m, 4H), 7.30 (d, J=9.2 Hz, 2H), 6.67 (d, J=8.9 Hz, 2H), 3.85 (q, J=7.0 Hz, 1H), 1.44 (d, J=6.9 Hz, 3H).

Example 19: Preparation of Compound 5

##STR00059##

[0183] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 51.7%.

[0184] .sup.1H NMR (400 MHz, DMSO) 7.55 (d, J=7.6 Hz, 2H), 7.51-7.43 (m, 3H), 7.40 (t, J=7.3 Hz, 1H), 7.30-7.18 (m, 2H), 6.77 (s, 1H), 5.65 (ddd, J=15.7, 6.0, 3.4 Hz, 2H), 3.95 (q, J=7.1 Hz, 1H), 3.62 (d, J=5.2 Hz, 1H), 2.36 (dd, J=12.9, 4.5 Hz, 2H), 1.98 (t, J=9.6 Hz, 3H), 1.86 (s, 1H), 1.78-1.72 (m, 1H), 1.43 (dd, J=7.1, 1.7 Hz, 3H).

[0185] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.55 (d, J=7.6 Hz, 2H), 7.51-7.43 (m, 3H), 7.40 (t, J=7.3 Hz, 1H), 7.30-7.18 (m, 2H), 6.77 (s, 1H), 5.65 (ddd, J=15.7, 6.0, 3.4 Hz, 2H), 3.95 (q, J=7.1 Hz, 1H), 3.62 (d, J=5.2 Hz, 1H), 2.36 (dd, J=12.9, 4.5 Hz, 2H), 1.98 (t, J=9.6 Hz, 3H), 1.86 (s, 1H), 1.78-1.72 (m, 1H), 1.43 (dd, J=7.1, 1.7 Hz, 3H). (R.20.6, 21.11.2023)

Example 20: Preparation of Compound 6

##STR00060##

[0186] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 40.8%.

[0187] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 12.61 (s, 1H), 7.89 (dd, J=8.1, 3.8 Hz, 1H), 7.57-7.52 (m, 2H), 7.48 (td, J=8.1, 2.2 Hz, 3H), 7.44-7.36 (m, 1H), 7.28-7.17 (m, 2H), 5.68 (qd, J=6.1, 3.7 Hz, 2H), 3.94 (ddd, J=13.0, 8.3, 3.3 Hz, 2H), 1.65-1.46 (m, 3H), 1.43 (d, J=7.2 Hz, 3H), 0.89-0.76 (m, 6H).

Example 21: Preparation of Compound 7

##STR00061##

[0188] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 48.2%.

[0189] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 12.75 (s, 1H), 9.22 (d, J=3.1 Hz, 1H), 7.93 (dd, J=8.3, 4.0 Hz, 1H), 7.54 (dd, J=8.4, 1.5 Hz, 2H), 7.50-7.45 (m, 3H), 7.43-7.40 (m, 1H), 7.26-7.17 (m, 2H), 7.05-6.98 (m, 2H), 6.66-6.62 (m, 2H), 5.66-5.56 (m, 2H), 4.10 (q, J=5.3 Hz, 2H), 4.08-4.03 (m, 1H), 3.92 (dd, J=7.2, 4.8 Hz, 1H), 1.41 (dd, J=7.1, 1.5 Hz, 3H).

Example 22: Preparation of Compound 8

##STR00062##

[0190] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 42.3%.

[0191] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.95 (d, J=8.3 Hz, 1H), 7.56-7.52 (m, 2H), 7.48 (t, J=8.0 Hz, 3H), 7.43-7.37 (m, 1H), 7.28-7.19 (m, 2H), 5.72-5.64 (m, 2H), 4.32 (td, J=8.1, 5.4 Hz, 1H), 3.96 (q, J=7.1 Hz, 1H), 2.76-2.68 (m, 1H), 2.58-2.51 (m, 1H), 1.44 (d, J=7.1 Hz, 3H).

Example 23: Preparation of Compound 9

##STR00063##

[0192] General Synthetic Method 2 was employed for preparation to yield a colorless oily liquid with a yield of 38.6%.

[0193] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.57-7.45 (m, 5H), 7.44-7.37 (m, 1H), 7.29-7.20 (m, 2H), 6.71 (q, J=5.4 Hz, 1H), 3.92 (q, J=7.1 Hz, 1H), 3.54 (d, J=11.3 Hz, 4H), 3.39-3.30 (m, 4H), 1.45-1.36 (m, 6H).

Example 24: Preparation of Compound 26

##STR00064##

[0194] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 61.4%.

[0195] .sup.1H NMR (600 MHz, DMSO) 7.50 (ddd, J=15.3, 13.6, 7.9 Hz, 5H), 7.41 (t, J=7.3 Hz, 1H), 7.26-7.19 (m, 2H), 5.73 (dd, J=21.7, 6.7 Hz, 2H), 3.96 (q, J=7.1 Hz, 1H), 3.50 (s, 4H), 2.51 (s, 4H), 1.44 (t, J=8.1 Hz, 3H).

Example 25: Preparation of Compound 27

##STR00065##

[0196] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 64.1%.

[0197] .sup.1H NMR (600 MHz, DMSO) 7.50 (dd, J=21.8, 13.5 Hz, 5H), 7.40 (t, J=6.8 Hz, 1H), 7.21 (s, 2H), 5.74 (d, J=6.5 Hz, 1H), 5.71 (d, J=5.9 Hz, 1H), 3.97 (q, J=7.1 Hz, 1H), 3.50 (s, 4H), 2.52 (s, 4H), 1.44 (d, J=7.1 Hz, 3H).

Example 26: Preparation of Compound 28

##STR00066##

[0198] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 63.4%.

[0199] .sup.1H NMR (400 MHz, DMSO) 7.53-7.46 (m, 5H), 7.42-7.38 (m, 1H), 7.21 (d, J=9.4 Hz, 2H), 5.70 (dd, J=33.6, 5.9 Hz, 2H), 3.94 (q, J=7.1 Hz, 1H), 3.07 (ddd, J=23.6, 14.1, 6.9 Hz, 4H), 1.46-1.23 (m, 7H), 0.79-0.63 (m, 6H).

Example 27: Preparation of Compound 29

##STR00067##

[0200] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 62.5%.

[0201] .sup.1H NMR (400 MHz, DMSO) 7.56-7.37 (m, 6H), 7.21 (d, J=9.4 Hz, 2H), 5.70 (dd, J=33.7, 5.9 Hz, 2H), 3.94 (q, J=7.1 Hz, 1H), 3.12-2.99 (m, 4H), 1.43 (d, J=7.1 Hz, 3H), 1.41-1.22 (m, 4H), 0.73 (dt, J=20.2, 7.4 Hz, 6H).

Example 28: Preparation of Compound 30

##STR00068##

[0202] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 67.6%.

[0203] .sup.1H NMR (600 MHz, DMSO) 7.56-7.37 (m, 6H), 7.21 (t, J=8.2 Hz, 2H), 5.70 (dd, J=20.6, 5.9 Hz, 2H), 4.72 (d, J=3.7 Hz, 1H), 3.96 (q, J=7.1 Hz, 1H), 3.62 (s, 3H), 3.05 (s, 2H), 1.67-1.61 (m, 2H), 1.43 (d, J=7.1 Hz, 2H), 1.25 (s, 3H).

Example 29: Preparation of Compound 31

##STR00069##

[0204] General Synthetic Method 2 was employed for preparation to yield a colorless liquid with a yield of 59.4%.

[0205] .sup.1H NMR (600 MHz, DMSO) 7.59-7.37 (m, 6H), 7.22 (t, J=8.2 Hz, 2H), 5.70 (dd, J=20.6, 5.9 Hz, 2H), 4.72 (d, J=3.7 Hz, 1H), 3.96 (q, J=7.1 Hz, 1H), 3.62 (s, 3H), 3.05 (s, 2H), 1.67-1.61 (m, 2H), 1.43 (d, J=7.1 Hz, 3H), 1.24 (s, 2H).

General Synthetic Method 3:

[0206] Method D was adopted for synthesis.

[0207] Formula (A) (1.0 eq.) was dissolved into anhydrous DCM, and oxalyl chloride (3.0 eq.) or acetyl chloride (1.2 to 1.5 eq.) and DMF at a catalytic amount were added dropwise, and stirred at room temperature for 0.5 h. The solution was drained to yield formula (G). Formula (G) was dissolved into a mixed solution of ethyl acetate: water (2:1) or into a DCM solution, added dropwise to a mixed system of formula (F) (2.0 eq.) and potassium carbonate (6.0 eq.) or triethylamine (1.5 eq.), and stirred at 20 C. to 25 C. for 4 to 12 h. 10 mL of ethyl acetate was added. The organic phases were washed with water (10 mL). The organic phases were collected, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography to yield the product.

Example 30: Preparation of Compound 32

##STR00070##

[0208] General Synthetic Method 3 was employed for preparation to yield a white solid with a yield of 42.7%.

[0209] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 13.20 (s, 1H), 7.94 (dd, J=7.8, 1.7 Hz, 1H), 7.63 (td, J=7.7, 1.8 Hz, 1H), 7.60-7.53 (m, 3H), 7.52-7.46 (m, 2H), 7.44-7.33 (m, 4H), 7.14 (dd, J=8.1, 1.2 Hz, 1H), 4.19 (q, J=7.2 Hz, 1H), 1.59 (d, J=7.2 Hz, 3H).

Example 31: Preparation of Compound 33

##STR00071##

[0210] General Synthetic Method 3 was employed for preparation to yield a colorless oily product with a yield of 56.5%.

[0211] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 8.55 (s, 1H), 7.56-7.52 (m, 2H), 7.48 (t, J=7.6 Hz, 3H), 7.43-7.38 (m, 1H), 7.27 (t, J=8.0 Hz, 2H), 7.00 (s, 1H), 6.73 (s, 1H), 5.31 (t, J=5.3 Hz, 1H), 5.15-5.05 (m, 2H), 4.53 (d, J=4.0 Hz, 2H), 3.95 (q, J=7.1 Hz, 1H), 2.12 (s, 3H), 1.46 (d, J=7.1 Hz, 3H).

General Synthetic Method 4:

[0212] Method E was adopted for synthesis.

Step 1:

[0213] Formula (J) (1.0 eq.), sodium bicarbonate (3.8 eq.), and tetrabutylammonium hydrogen sulfate (0.1 eq.) were dissolved into a mixed solution of dichloromethane: water (1:1), and stirred at room temperature for 5 min. Chloromethyl chlorosulfonate (1.1 to 2 eq.) was dissolved into DCM, added dropwise to the above reaction solution, and stirred at room temperature for 1 h. The organic phases were washed with water (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield formula (H).

[0214] Alternatively, formula (J) (1 eq.) was dissolved into DMF. To the solution were added imidazole (2 eq.) and tert-butyldimethylsilyl chloride (2 eq.) or benzyl bromide (2 eq.) in sequence, and stirred at room temperature for 1 h. The mixture was poured into 15 mL of water, and extracted with ethyl acetate (10 mL*3). The organic phases were washed with a saturated aqueous sodium chloride solution (20 mL) three times. The organic phases were collected, dried over anhydrous sodium sulfate, and distilled under reduced pressure to yield protective group-protected formula (J). Subsequently, the first step reaction was carried out to yield protective group-protected formula (H).

[0215] Alternatively, formula (J) (1 eq.) was dissolved into dry DCM. Oxalyl chloride (1.5 eq.) was added under nitrogen protection, and then one drop of DMF was added, stirred at room temperature for 1 h, and distilled under reduced pressure to yield an acyl chloride compound. The acyl chloride compound was dissolved into DCM, and zinc chloride (0.02 eq.) was added. Subsequently, acetaldehyde (1 eq.) was added at 15 C. under nitrogen protection. The reaction solution was reacted at room temperature for 16 h, and concentrated under reduced pressure. Afterwards, the residue was dissolved into 20 mL of ethyl acetate. The resultant was washed with water (20 mL), a saturated sodium bicarbonate solution (20 mL), and a saturated aqueous sodium chloride solution (20 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was evaporated to dryness under reduced pressure to yield a compound of formula (H).

Step 2:

[0216] Formula (A) (1.0 eq.) was dissolved into DMF. Triethylamine (1.5 eq.) or potassium carbonate (1.6 to 2.0 eq.) was added, and sodium iodide (1.1 eq.) might or might not be added, and stirred at 20 C. to 50 C. Formula (H) or protective group-protected formula (H) (1.2 eq.) was dissolved into DMF, slowly added to the above reaction solution, and reacted for 3 to 4 h. 20 mL of ethyl acetate was added. Thereafter, the organic phases were washed with water (20 mL) and a saturated aqueous sodium chloride solution (20 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by silica gel column chromatography to yield the product formula (III) or protective group-containing formula (III).

[0217] The tert-butyldimethylsilyl was de-protected from the protective group-protected formula (III) by hydrogen reduction or by acid or base or tetrabutylammonium fluoride to yield formula (III).

Example 32: Preparation of Compound 34

##STR00072##

[0218] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 20.0%.

[0219] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.56-7.44 (m, 5H), 7.41 (td, J=7.0, 1.6 Hz, 1H), 7.23-7.12 (m, 2H), 7.12-7.01 (m, 4H), 5.81-5.61 (m, 2H), 3.90 (p, J=7.1 Hz, 1H), 3.76 (p, J=6.9 Hz, 1H), 2.36 (t, J=7.2 Hz, 2H), 1.75 (dh, J=13.2, 6.6 Hz, 1H), 1.34 (ddd, J=19.4, 11.2, 7.2 Hz, 6H), 0.81 (dd, J=6.6, 4.4 Hz, 6H).

Example 33: Preparation of Compound 35

##STR00073##

[0220] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 38.7%.

[0221] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 10.48 (s, 1H), 7.80-7.75 (m, 2H), 7.46 (d, J=4.6 Hz, 4H), 7.43-7.37 (m, 2H), 7.25-7.18 (m, 2H), 6.88-6.82 (m, 2H), 5.96-5.89 (m, 2H), 3.99 (q, J=7.1 Hz, 1H), 1.44 (d, J=7.1 Hz, 3H).

Example 34: Preparation of Compound 36

##STR00074##

[0222] General Synthetic Method 4 was employed for preparation to yield a white solid with a yield of 47.4%.

[0223] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 7.88 (dd, J=7.8, 1.7 Hz, 1H), 7.75-7.69 (m, 1H), 7.51-7.37 (m, 7H), 7.28-7.20 (m, 3H), 5.96-5.90 (m, 2H), 4.01 (q, J=7.1 Hz, 1H), 2.24 (s, 3H), 1.46 (d, J=7.1 Hz, 3H).

Example 35: Preparation of Compound 37

##STR00075##

[0224] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 47.6%.

[0225] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.88 (dd, J=7.8, 1.7 Hz, 1H), 7.75-7.69 (m, 1H), 7.49-7.38 (m, 7H), 7.28-7.20 (m, 3H), 5.95-5.91 (m, 1H), 4.02 (dd, J=7.1, 5.8 Hz, 1H), 2.24 (s, 3H), 1.46 (d, J=7.1 Hz, 3H).

Example 36: Preparation of Compound 38

##STR00076##

[0226] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 43.4%.

[0227] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 10.29 (s, 1H), 7.67 (dd, J=7.9, 1.8 Hz, 1H), 7.55-7.38 (m, 7H), 7.27-7.20 (m, 2H), 6.99 (d, J=8.4 Hz, 1H), 6.91 (t, J=7.6 Hz, 1H), 6.04-5.95 (m, 2H), 4.02 (q, J=7.1 Hz, 1H), 1.46 (d, J=7.1 Hz, 3H).

Example 37: Preparation of Compound 39

##STR00077##

[0228] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 59.2%.

[0229] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.51-7.37 (m, 6H), 7.30-7.15 (m, 2H), 7.09-6.95 (m, 3H), 5.91 (q, J=6.0 Hz, 2H), 4.00 (q, J=7.1 Hz, 1H), 2.88 (s, 6H), 2.18 (s, 3H), 1.45 (d, J=7.1 Hz, 3H).

Example 38: Preparation of Compound 40

##STR00078##

[0230] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 61.4%.

[0231] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 9.90 (s, 1H), 7.48-7.38 (m, 6H), 7.37-7.30 (m, 3H), 7.26-7.18 (m, 2H), 7.06 (ddd, J=7.4, 2.7, 1.7 Hz, 1H), 5.95 (q, J=5.9 Hz, 2H), 4.01 (q, J=7.1 Hz, 1H), 1.45 (d, J=7.1 Hz, 3H).

Example 39: Preparation of Compound 41

##STR00079##

[0232] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 46.7%.

[0233] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 10.35 (s, 1H), 7.46 (d, J=5.4 Hz, 4H), 7.44-7.36 (m, 3H), 7.22 (dd, J=11.9, 1.7 Hz, 1H), 7.19 (dd, J=7.9, 1.8 Hz, 1H), 6.28 (dd, J=9.2, 2.5 Hz, 1H), 6.07 (d, J=2.5 Hz, 1H), 5.97-5.89 (m, 2H), 3.99 (t, J=7.1 Hz, 1H), 2.97 (s, 6H), 1.44 (d, J=7.1 Hz, 3H).

Example 40: Preparation of Compound 42

##STR00080##

[0234] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 56.35%.

[0235] .sup.1H NMR (600 MHz, DMSO) & 10.48 (s, 1H), 7.78 (d, J=8.6 Hz, 2H), 7.45 (t, J=11.3 Hz, 4H), 7.42-7.36 (m, 2H), 7.21 (t, J=11.3 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 5.92 (dd, J=16.2, 5.9 Hz, 2H), 3.99 (q, J=7.1 Hz, 1H), 1.44 (d, J=7.1 Hz, 3H).

Example 41: Preparation of Compound 43

##STR00081##

[0236] General Synthetic Method 4 was employed for preparation to yield a colorless oily product with a yield of 58.6%.

[0237] .sup.1H NMR (600 MHz, DMSO) 10.48 (s, 1H), 7.78 (d, J=8.6 Hz, 2H), 7.45 (t, J=11.3 Hz, 4H), 7.42-7.36 (m, 2H), 7.21 (t, J=11.3 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 5.92 (dd, J=16.2, 5.9 Hz, 2H), 3.99 (q, J=7.1 Hz, 1H), 1.44 (d, J=7.1 Hz, 3H).

Example 42: Preparation of Compound 44

##STR00082##

[0238] General Synthetic Method 3 was employed for preparation to yield a colorless oily product with a yield of 62.5%.

[0239] .sup.1H NMR (600 MHz, DMSO) 8.51 (s, 1H), 7.56-7.43 (m, 6H), 7.40 (t, J=7.3 Hz, 1H), 7.26 (t, J=8.4 Hz, 2H), 6.99 (s, 1H), 6.72 (s, 1H), 5.27 (t, J=5.3 Hz, 1H), 5.09 (q, J=12.7 Hz, 2H), 4.52 (d, J=4.8 Hz, 2H), 2.11 (s, 3H), 1.45 (d, J=7.1 Hz, 3H).

Example 43: Preparation of Compound 45

##STR00083##

[0240] General Synthetic Method 3 was employed for preparation to yield a colorless oily product with a yield of 69.4%.

[0241] .sup.1H NMR (600 MHz, DMSO) 8.52 (s, 1H), 7.57-7.45 (m, 5H), 7.40 (t, J=7.4 Hz, 1H), 7.26 (t, J=8.4 Hz, 2H), 6.99 (s, 1H), 6.72 (s, 1H), 5.28 (t, J=5.3 Hz, 1H), 5.09 (q, J=12.7 Hz, 2H), 4.52 (d, J=5.1 Hz, 2H), 3.95 (q, J=7.0 Hz, 1H), 2.11 (s, 3H), 1.45 (d, J=7.1 Hz, 3H).

General Synthetic Method 5:

[0242] Method C was adopted for synthesis.

[0243] Formula (A) (1.0 eq.), formula (F) (1.2 eq.), EDCI (1.5 eq.), and DMAP (0.1 eq.) were added to 5 mL of DMF, and stirred at room temperature for 12 h. 50 mL of ethyl acetate was added. Subsequently, the organic phases were washed with a saturated aqueous ammonium chloride solution (50 mL*2), water (50 mL), and a saturated aqueous sodium chloride solution (50 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by column chromatography to yield the product.

Example 44: Preparation of Compound 46

##STR00084##

[0244] General Synthetic Method 5 was employed for preparation to yield a colorless oily product with a yield of 51.7%.

[0245] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.57-7.44 (m, 5H), 7.44-7.37 (m, 1H), 7.27-7.18 (m, 4H), 6.95-6.85 (m, 2H), 5.11-5.00 (m, 2H), 3.92 (q, J=7.1 Hz, 1H), 3.73 (s, 3H), 1.43 (d, J=7.1 Hz, 3H).

Example 45: Preparation of Compound 47

##STR00085##

[0246] General Synthetic Method 4 was employed for preparation to yield a white solid with a yield of 92.9%.

[0247] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 7.59-7.45 (m, 5H), 7.40 (t, J=7.3 Hz, 1H), 7.26 (t, J=10.2 Hz, 2H), 6.40 (m, 3H), 5.07 (d, J=22.8 Hz, 2H), 3.99 (d, J=7.1 Hz, 1H), 3.67 (s, 6H), 1.47 (d, J=7.1 Hz, 3H).

Example 46: Preparation of Compound 48

##STR00086##

[0248] General Synthetic Method 3 was employed for preparation to yield a white solid with a yield of 40.7%.

[0249] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 9.73 (s, 1H), 7.57-7.38 (m, 6H), 7.27-7.19 (m, 2H), 7.13 (m, 2H), 6.83 (dd, J=8.1, 1.1 Hz, 1H), 6.75 (td, J=7.5, 1.2 Hz, 1H), 5.08 (d, J=3.8 Hz, 2H), 3.94 (q, J=7.1 Hz, 1H), 1.45 (d, J=7.1 Hz, 3H).

Example 47: Preparation of Compound 49

##STR00087##

[0250] General Synthetic Method 3 was employed for preparation to yield a colorless liquid with a yield of 77.5%.

[0251] .sup.1H NMR (600 MHz, CDCl.sub.3) 7.53 (d, J=7.8 Hz, 2H), 7.43 (t, J=7.6 Hz, 2H), 7.36 (m, 2H), 7.15-7.07 (m, 2H), 6.80-6.70 (m, 3H), 5.93 (m, 2H), 5.08-4.93 (m, 2H), 3.77 (q, J=7.2 Hz, 1H), 1.53 (d, J=7.1 Hz, 3H).

Example 48: Preparation of Compound 50

##STR00088##

[0252] General Synthetic Method 5 was employed for preparation to yield a colorless liquid with a yield of 60.3%.

[0253] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 7.58-7.52 (m, 2H), 7.48 (m, 3H), 7.45-7.37 (m, 1H), 7.31 (td, J=7.9, 1.8 Hz, 1H), 7.27-7.14 (m, 3H), 7.00 (d, J=8.2 Hz, 1H), 6.90 (t, J=7.4 Hz, 1H), 5.54-4.86 (m, 2H), 3.94 (q, J=7.1 Hz, 1H), 3.74 (s, 3H), 1.45 (d, J=7.1 Hz, 3H).

Example 49: Preparation of Compound 51

##STR00089##

[0254] General Synthetic Method 3 was employed for preparation to yield a colorless liquid with a yield of 48.3%.

[0255] .sup.1H NMR (400 MHz, DMSO-d.sub.6) 7.55-7.45 (m, 5H), 7.45-7.37 (m, 1H), 7.30-7.24 (m, 2H), 6.55 (s, 2H), 5.14-5.00 (m, 2H), 3.99 (q, J=7.1 Hz, 1H), 3.68 (s, 6H), 3.62 (s, 3H), 1.47 (d, J=7.2 Hz, 3H).

Example 50: Preparation of Compound 52

##STR00090##

[0256] General Synthetic Method 5 was employed for preparation to yield a colorless liquid with a yield of 5.6%.

[0257] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 9.46 (s, 1H), 7.63-7.32 (m, 6H), 7.24-7.05 (m, 4H), 6.71 (d, J=8.4 Hz, 2H), 5.00 (q, J=12.0 Hz, 2H), 3.91 (q, J=7.1 Hz, 1H), 1.43 (d, J=7.1 Hz, 3H).

General Synthetic Method 6:

[0258] Method A was adopted for synthesis.

Step 1: (Synthesized by Step 1)

[0259] Acid (1 eq.) was dispersed in DCM. An aqueous solution of tetrabutylammonium hydrogen sulfate and sodium bicarbonate (4 eq.) as catalysts was added. Chloromethyl chlorosulfonate (1.2 eq.) was added while stirring. The reaction solution was reacted at room temperature for 4 h and left stand for layering. The organic phases were collected, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography to yield chlorinated formula (B).

Step 2: (Synthesized by Step 2)

[0260] Chlorinated formula (B) was dissolved into acetonitrile, and sodium iodide (1.2 eq.) was added and reacted at 40 C. for 1 h to yield iodinated formula (B).

Step 3:

[0261] To the iodinated formula (B), formula (A) (1 eq.) and potassium carbonate (1.2 eq.) were added and further reacted for 10 h. The solvent was removed under reduced pressure, and ethyl acetate and saturated sodium chloride were added for extraction. The organic phases were collected, dried over anhydrous sodium sulfate, concentrated and separated to yield the product formula (II).

Example 51: Preparation of Compound 53

##STR00091##

[0262] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 65.32%.

[0263] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.0, 1.5 Hz, 2H), 7.48-7.34 (m, 4H), 7.17-7.08 (m, 2H), 6.67 (s, 2H), 5.75 (q, J=5.6 Hz, 2H), 3.80 (q, J=7.2 Hz, 1H), 3.47 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.67-1.50 (m, 8H), 1.34-1.23 (m, 3H).

[0264] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.0, 1.5 Hz, 2H), 7.48-7.34 (m, 4H), 7.17-7.08 (m, 2H), 6.67 (s, 2H), 5.75 (q, J=5.6 Hz, 2H), 3.80 (q, J=7.2 Hz, 1H), 3.47 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.67-1.50 (m, 7H), 1.34-1.23 (m, 2H). (R.20.6, 21.11.2023)

Example 52: Preparation of Compound 54

##STR00092##

[0265] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 12.33%.

[0266] .sup.1H NMR (400 MHz, Chloroform-d) 7.55 (d, J=7.6 Hz, 2H), 7.48-7.36 (m, 4H), 7.16-7.09 (m, 2H), 5.84-5.76 (m, 2H), 5.74 (s, 2H), 3.81 (q, J=7.1 Hz, 1H), 2.80 (s, 3H), 1.58 (s, 2H).

Example 53: Preparation of Compound 55

##STR00093##

[0267] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 19.87%.

[0268] .sup.1H NMR (400 MHz, Chloroform-d) 7.54 (dt, J=6.8, 1.5 Hz, 2H), 7.47-7.34 (m, 4H), 7.17-7.09 (m, 2H), 5.77-5.70 (m, 2H), 3.88-3.77 (m, 4H), 2.76-2.71 (m, 3H), 2.65 (td, J=7.0, 0.9 Hz, 2H), 1.57 (s, 3H).

Example 54: Preparation of Compound 56

##STR00094##

[0269] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 21.66%.

[0270] .sup.1H NMR (400 MHz, Chloroform-d) 7.56-7.52 (m, 2H), 7.48-7.34 (m, 4H), 7.17-7.09 (m, 2H), 6.68 (s, 2H), 5.79-5.70 (m, 2H), 3.81 (td, J=7.1, 3.5 Hz, 3H), 2.69-2.64 (m, 2H), 1.56 (d, J=7.2 Hz, 3H).

Example 55: Preparation of Compound 57

##STR00095##

[0271] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 35.37%.

[0272] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.2, 1.5 Hz, 2H), 7.50-7.33 (m, 4H), 7.19-7.06 (m, 2H), 6.66 (s, 2H), 5.84-5.70 (m, 2H), 3.81 (q, J=7.1 Hz, 1H), 3.55 (t, J=6.8 Hz, 2H), 2.33 (d, J=7.4 Hz, 2H), 1.89 (p, J=7.1 Hz, 2H), 1.56 (d, J=7.2 Hz, 3H).

Example 56: Preparation of Compound 58

##STR00096##

[0273] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 55.78%.

[0274] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.1, 1.5 Hz, 2H), 7.48-7.32 (m, 4H), 7.18-7.07 (m, 2H), 6.68 (s, 2H), 5.80-5.72 (m, 2H), 3.79 (q, J=7.2 Hz, 1H), 3.54-3.46 (m, 2H), 2.34-2.26 (m, 2H), 1.62-1.50 (m, 7H), 1.24 (dt, J=11.6, 3.6 Hz, 12H).

Example 57: Preparation of Compound 59

##STR00097##

[0275] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 56.65%.

[0276] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.0, 1.5 Hz, 2H), 7.48-7.32 (m, 4H), 7.15 (d, J=1.8 Hz, 1H), 7.14-7.07 (m, 1H), 6.29 (q, J=1.8 Hz, 1H), 5.75 (q, J=5.6 Hz, 2H), 3.80 (q, J=7.1 Hz, 1H), 3.45 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 2.07 (d, J=1.9 Hz, 3H), 1.65-1.49 (m, 6H), 1.34-1.21 (m, 3H).

Example 58: Preparation of Compound 60

##STR00098##

[0277] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 54.53%.

[0278] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.1, 1.5 Hz, 2H), 7.48-7.32 (m, 4H), 7.15 (d, J=1.8 Hz, 1H), 7.14-7.07 (m, 1H), 5.80-5.71 (m, 2H), 3.80 (q, J=7.2 Hz, 1H), 3.44 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.95 (s, 6H), 1.64-1.45 (m, 6H), 1.28 (dtd, J=10.7, 7.6, 7.2, 4.8 Hz, 3H).

Example 59: Preparation of Compound 61

##STR00099##

[0279] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 89.25%.

[0280] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.2, 1.5 Hz, 2H), 7.49-7.32 (m, 4H), 7.17-7.07 (m, 2H), 6.67 (s, 2H), 5.75 (q, J=5.6 Hz, 2H), 3.80 (q, J=7.1 Hz, 1H), 3.48 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.67-1.50 (m, 8H), 1.32-1.21 (m, 3H).

[0281] .sup.1H NMR (400 MHz, Chloroform-d) 7.53 (dt, J=8.2, 1.5 Hz, 2H), 7.49-7.32 (m, 4H), 7.17-7.07 (m, 2H), 6.67 (s, 2H), 5.75 (q, J=5.6 Hz, 2H), 3.80 (q, J=7.1 Hz, 1H), 3.48 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.67-1.50 (m, 7H), 1.32-1.21 (m, 2H). (R.20.6, 21.11.2023)

Example 60: Preparation of Compound 62

##STR00100##

[0282] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 51.38%.

[0283] .sup.1H NMR (400 MHz, Chloroform-d) 7.58-7.49 (m, 2H), 7.45 (dt, J=6.9, 1.3 Hz, 1H), 7.44-7.32 (m, 3H), 7.18-7.07 (m, 2H), 6.67 (s, 2H), 5.75 (q, J=5.6 Hz, 2H), 3.80 (q, J=7.2 Hz, 1H), 3.48 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.67-1.59 (m, 3H), 1.59-1.52 (m, 5H), 1.34-1.22 (m, 3H).

[0284] .sup.1H NMR (400 MHz, Chloroform-d) 7.58-7.49 (m, 2H), 7.45 (dt, J=6.9, 1.3 Hz, 1H), 7.44-7.32 (m, 3H), 7.18-7.07 (m, 2H), 6.67 (s, 2H), 5.75 (q, J=5.6 Hz, 2H), 3.80 (q, J=7.2 Hz, 1H), 3.48 (t, J=7.2 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 1.67-1.59 (m, 2H), 1.59-1.52 (m, 5H), 1.34-1.22 (m, 2H). (R.20.6, 21.11.2023)

Example 61: Preparation of Compound 63

##STR00101##

[0285] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 55.51%.

[0286] .sup.1H NMR (400 MHz, Chloroform-d) 7.57-7.49 (m, 2H), 7.49-7.32 (m, 4H), 7.18-7.07 (m, 2H), 6.67 (s, 2H), 5.80-5.73 (m, 2H), 3.79 (q, J=7.1 Hz, 1H), 3.52-3.43 (m, 2H), 2.36-2.25 (m, 2H), 1.63-1.51 (m, 8H), 1.35-1.19 (m, 3H).

Example 62: Preparation of Compound 64

##STR00102##

[0287] General Synthetic Method 6 was employed for preparation to yield a colorless liquid with a yield of 56.93%.

[0288] .sup.1H NMR (400 MHz, Chloroform-d) 7.57-7.49 (m, 2H), 7.48-7.33 (m, 4H), 7.14 (dd, J=7.9, 1.8 Hz, 1H), 7.11 (dd, J=11.3, 1.8 Hz, 1H), 6.67 (s, 2H), 5.80-5.71 (m, 2H), 3.80 (q, J=7.1 Hz, 1H), 3.53-3.46 (m, 2H), 2.39-2.31 (m, 2H), 1.59 (s, 3H), 1.55 (d, J=7.0 Hz, 4H).

Example 63: Preparation of Compound 65

##STR00103##

[0289] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 30.98%.

[0290] .sup.1H NMR (600 MHz, Chloroform-d) 7.52 (dd, J=7.1, 1.5 Hz, 2H), 7.43 (t, J=7.6 Hz, 2H), 7.41-7.35 (m, 2H), 7.17-7.10 (m, 2H), 5.79 (s, 2H), 3.79 (q, J=7.1 Hz, 1H), 3.28-3.08 (m, 4H), 1.55 (d, J=7.1 Hz, 3H), 1.49 (p, J=7.6 Hz, 2H), 1.39 (p, J=7.4 Hz, 2H), 1.29 (p, J=7.4 Hz, 2H), 1.25-1.18 (m, 2H), 0.91 (m, 6H).

Example 64: Preparation of Compound 66

##STR00104##

[0291] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 29.75%.

[0292] .sup.1H NMR (600 MHz, Chloroform-d) 7.52 (dt, J=8.1, 1.4 Hz, 2H), 7.42 (dd, J=8.5, 6.9 Hz, 2H), 7.39-7.33 (m, 2H), 7.16-7.10 (m, 2H), 5.78 (s, 2H), 3.79 (q, J=7.1 Hz, 1H), 3.27-3.16 (m, 2H), 3.11 (td, J=7.3, 4.6 Hz, 2H), 1.54 (d, J=7.2 Hz, 3H), 1.49 (p, J=7.5 Hz, 2H), 1.39 (p, J=7.5 Hz, 2H), 1.28 (q, J=7.5 Hz, 2H), 1.21 (h, J=7.5 Hz, 2H), 0.88 (dt, J=22.8, 7.4 Hz, 6H).

Example 65: Preparation of Compound 67

##STR00105##

[0293] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 77.35%.

[0294] .sup.1H NMR (600 MHz, Chloroform-d) 7.52 (dt, J=8.0, 1.5 Hz, 2H), 7.43 (dd, J=8.5, 6.9 Hz, 2H), 7.41-7.33 (m, 2H), 7.15 (dd, J=7.9, 1.9 Hz, 1H), 7.11 (dd, J=11.5, 1.8 Hz, 1H), 5.81-5.75 (m, 2H), 3.82-3.77 (m, 1H), 3.26-3.20 (m, 1H), 3.15 (h, J=6.9 Hz, 1H), 2.85 (d, J=45.8 Hz, 3H), 1.54 (d, J=7.0 Hz, 4H), 1.49 (t, J=7.2 Hz, 1H), 1.42 (t, J=7.2 Hz, 1H), 1.26 (s, 4H), 1.21 (s, 1H), 0.86 (t, J=6.8 Hz, 3H).

Example 66: Preparation of Compound 68

##STR00106##

[0295] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 76.59%.

[0296] .sup.1H NMR (600 MHz, Chloroform-d) 7.52 (dt, J=8.1, 1.4 Hz, 2H), 7.46-7.33 (m, 4H), 7.18-7.09 (m, 2H), 5.82-5.73 (m, 2H), 3.78-3.80 (m, 1H), 3.25-3.20 (m, 1H), 3.15 (d, J=8.0 Hz, 1H), 2.85 (d, J=45.8 Hz, 3H), 1.42 (t, J=7.2 Hz, 1H), 1.26 (s, 7H), 0.87 (t, J=6.5 Hz, 3H).

[0297] .sup.1H NMR (600 MHz, Chloroform-d) 7.52 (dt, J=8.1, 1.4 Hz, 2H), 7.46-7.33 (m, 4H), 7.18-7.08 (m, 2H), 5.84-5.72 (m, 2H), 3.79 (dd, J=7.4, 3.2 Hz, 1H), 3.25-3.08 (m, 2H), 2.85 (d, J=45.8 Hz, 3H), 1.55 (d, J=7.1 Hz, 3H), 1.51-1.39 (m, 2H), 1.24 (d, J=23.8 Hz, 6H), 0.86 (t, J=6.5 Hz, 3H). (R.20.6, 21.11.2023)

Example 67: Preparation of Compound 69

##STR00107##

[0298] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 81.27%.

[0299] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 7.52 (dt, J=8.2, 1.5 Hz, 2H), 7.50-7.45 (m, 3H), 7.44-7.39 (m, 1H), 7.23-7.19 (m, 2H), 5.75 (d, J=5.7 Hz, 1H), 5.67 (d, J=5.9 Hz, 1H), 3.93 (q, J=7.1 Hz, 1H), 3.02-2.90 (m, 4H), 1.86 (dt, J=13.8, 7.0 Hz, 1H), 1.76 (dt, J=13.8, 6.9 Hz, 1H), 1.43 (d, J=7.1 Hz, 3H), 0.74 (dt, J=33.3, 6.4 Hz, 12H).

Example 68: Preparation of Compound 70

##STR00108##

[0300] General Synthetic Method 2 was employed for preparation to yield a colorless oily product with a yield of 80.52%.

[0301] .sup.1H NMR (600 MHz, DMSO-d.sub.6) 7.54-7.46 (m, 5H), 7.42-7.38 (m, 1H), 7.23-7.19 (m, 2H), 5.75 (d, J=5.7 Hz, 1H), 5.67 (d, J=5.9 Hz, 1H), 3.93 (q, J=7.1 Hz, 1H), 3.03-2.90 (m, 4H), 1.86 (dt, J=13.6, 6.9 Hz, 1H), 1.75 (dq, J=13.7, 6.9 Hz, 1H), 1.43 (d, J=7.1 Hz, 3H), 0.74 (dt, J=33.3, 6.5 Hz, 12H).

TEST EXAMPLES

Test Example 1: In Vivo Pharmacokinetic Assay in Rats

[0302] Experimental method: Adult female Sprague Dawley rats, aged 8-10 weeks and weighing 20020 g, were randomly grouped, with 3 rats in each group. Rats in each of the groups were administered by gavage at a dose of 50 mg/kg of flurbiprofen and an equimolar dose of other example compounds to 50 mg/kg of flurbiprofen, respectively. After gavage administration, blood was collected at 0.0833 h, 0.25 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 9 h, 12 h, and 24 h into sodium heparin anticoagulant tubes, respectively. The blood was collected by the following method: 250 L of blood were collected from the orbital venous plexuses of the rats. After blood collection, the blood samples were centrifuged at 12000 rpm in a centrifuge for 5 min. All plasma was aspirated into a 1.5-mL centrifuge tube, and the plasma was stored in a refrigerator at 80 C.

[0303] The pharmacokinetic parameters were determined by the external standard curve method. Sample processing: after the cryopreserved samples were removed and restored to room temperature, the samples were vortexed evenly and then diluted two folds with methanol; the sample solution was diluted 5 folds by adding a mixed extractant of 0.5% formic acid-containing acetonitrile:methanol=7:3, and subjected to vortex oscillation for 1 min. Subsequently, the resultant was centrifuged at 4 C. and 12000 rpm for 10 min, and then 5 L of the supernatant was measured for assay. The pharmacokinetic parameters in the Examples were calculated using the Winnonlin software. The results were as shown in Table 1.

[0304] The results showed that the exposure or half-life of the metabolites of the above compounds of the present disclosure in the rat plasma was significantly increased as compared to flurbiprofen.

TABLE-US-00001 TABLE 1 Pharmacokinetic Parameters for Test Drugs Prototype Drug Flurbiprofen Compounds AUC C.sub.max t.sub.1/2 AUC C.sub.max t.sub.1/2 Flurbiprofen 752644 83652 110628 9471 3.74 1.00 Compound 8.75 1.53 1.56 0.509 9.08 1.44 858774 351764 73992 30524 8.50 3.78 33 Compound 1 758774 351764 63992 30524 8.50 3.78 Compound 2 183 85.9 27.1 7.20 14.0 9.88 1644486 155721 402771 35343 3.80 0.753 Compound 9 914578 259601 88698 6884 6.58 1.46 Compound 973908 93514 89096 8691 5.28 0.553 16 Compound 990213 86222 86636 9073 7.61 1.95 18 Compound 858829 158715 72804 20243 8.45 4.54 34 Compound 796631 71412 62248 1729 7.34 3.15 35 Compound 63012 11787 3865 178 8.10 4.42 7901097 2231756 593596 134139 5.14 0.530 25 Compound 844289 132155 83071 5316 6.54 0.693 36 Compound 896631 71412 72248 1729 7.34 3.15 27 Compound 752414 86592 68454 11858 4.89 0.02 46 Compound 884288 49939 77206 11698 5.44 0.10 47

Test Example 2: Anti-Inflammatory Effect on Toe Swelling in Experimental Rats

[0305] Experimental method: Male SD rats weighing 150-160 g were randomly grouped, with 10 rats in each group. The rats were intraperitoneally injected with saline, the compounds of the present disclosure, and the control drug flurbiprofen or flurbiprofen axetil respectively, all of which were administered at a dose of 10 mg/kg and a dosing volume of 10 L/g. At 1 h after administration, 100 L of 1% -carrageenan was injected into the right hind toe of each rat to induce inflammation. Afterwards, the paw volume was measured every 1 h using a paw volume meter to calculate the swelling inhibition rate.

[0306] The results showed that all the compounds of the present disclosure in Table 2 exhibited a better anti-inflammatory effect as compared to flurbiprofen.

TABLE-US-00002 TABLE 2 Anti-Inflammatory Effect on - Carrageenan-Induced Rat Toe Swelling Toe Swelling Toe Swelling Inhibition Inhibition Groups Dose (mg/kg) Rate at 6 h Rate at 24 h Model control Equal volume group of saline Flurbiprofen 10.0 35.50%** 29.95%** Flurbiprofen axetil 10.0 35.53%** 22.85%** Compound 33 10.0 55.52%*** 35.83%*** Compound 2 10.0 42.94%** 34.09%** Compound 3 10.0 45.29%* 28.10%* Compound 7 10.0 47.88%*** 21.48%* Compound 13 10.0 46.03%** 37.01%** Compound 20 10.0 52.72%*** 45.00%*** Compound 35 10.0 54.63% 49.84% Compound 36 10.0 45.29%* 28.10% Compound 41 10.0 43.04%** 32.23%** Compound 29 10.0 45.82%*** 29.56%** Compound 31 10.0 45.35%** 31.95%** Compound 47 10.0 49.26%*** 33.85%** Compound 48 10.0 44.10%** 33.85%** Compound 53 10.0 69.04%*** 75.24%*** Compound 55 10.0 36.66%* 41.39%** Compound 57 10.0 43.84%** 43.42%** Compound 58 10.0 43.64%** 47.65%*** Compound 61 10.0 61.72%*** 52.93%*** Compound 63 10.0 47.92%*** 32.31%** Compound 64 10.0 54.28%*** 40.36%*** Compound 65 10.0 43.08%*** 43.84%*** Compound 67 10.0 48.62%*** 57.31%*** Compound 69 10.0 65.91%*** 70.62%*** *denoted that the P value was less than 0.05, **denoted that the P value was less than 0.01, ***denoted that the P value was less than 0.001.

Test Example 3: Effects on Dry Yeast-Induced Fever in Rats

[0307] Experimental method: Male SD rats, aged 4 weeks, were randomly grouped, with 10 rats in each group. Under the ambient temperature of 20 C. to 21 C. and the humidity of 40% to 70%, the body temperatures were screened and the average body temperature was at about 37.4 C., with the elimination rate of about 10%. The rats were intraperitoneally injected with saline, the compounds of the present disclosure or the control drug flurbiprofen respectively, all of which were administered at a dose of 10 mg/kg and a dosing volume of 10 L/g. At 20 min after administration, 20% active dry yeast suspension was injected subcutaneously. After modeling, the rectal temperatures were measured at 4 h and 8 h.

[0308] The results showed that all the compounds of the present disclosure in Table 3 exhibited a better antipyretic effect as compared to flurbiprofen.

TABLE-US-00003 TABLE 3 Antipyretic Effect on Dry Yeast-Induced Rat Fever Models Temp. at 4 h Temp. at 8 h After Dosing After Dosing Groups Dose (mg/kg) ( C.) ( C.) Model control Equal volume of 38.58 0.42 39.52 0.34 group saline Flurbiprofen 10.0 37.49 0.43 37.67 0.39 Compound 33 10.0 37.18 0.18 37.27 0.28 Compound 2 10.0 37.10 0.17 37.32 0.27 Compound 9 10.0 37.17 0.23 37.10 0.37 Compound 13 10.0 37.10 0.172 37.32 0.27 Compound 15 10.0 37.16 0.16 37.27 0.24 Compound 20 10.0 37.09 0.25 37.27 0.26 Compound 36 10.0 37.38 0.31 37.24 0.16 Compound 41 10.0 37.19 0.35 37.30 0.31 Compound 35 10.0 37.15 0.21 37.29 0.30 Compound 29 10.0 37.12 0.13 37.35 0.23 Compound 31 10.0 37.12 0.30 37.22 0.30 Compound 47 10.0 37.17 0.27 37.26 0.22 Compound 48 10.0 37.11 0.23 37.21 0.25 Compound 53 10.0 37.04 0.20 37.02 0.30 Compound 61 10.0 37.14 0.29 37.06 0.32 Compound 63 10.0 37.05 0.18 37.14 0.25 Compound 64 10.0 37.09 0.16 37.18 0.26 Compound 65 10.0 37.10 0.20 37.24 0.23 Compound 67 10.0 37.17 0.19 37.16 0.20 Compound 69 10.0 37.09 0.18 37.13 0.27

Test Example 4: Analgesic and Anti-Inflammatory Effects on Collagen-Induced Rheumatoid Arthritis (CIA)

[0309] Experimental method: Female Lewis rats, aged 6-8 weeks, were randomly grouped, with 8 rats in each group. Under the ambient temperature of 20.5 C. to 24.5 C. and the humidity of 40% to 70%, the light period was 12-h bright and 12-h dark. Type II collagen was mixed with Freund's incomplete adjuvant (IFA) at a ratio of 1:1 and fully emulsified on ice before use. 100 L of the mixed solution was injected intradermally at the part 2 to 3 cm from the base of the rat tail, and 50 L of the mixed solution was injected into the bases of both hind limbs separately. The rats in the blank control group were injected with an equal volume of saline. IFA was used for re-immunization 7 days later. The rats were observed for the incidence of disease every day after the second immunization. Rats with a total score of more than 2 on both hind limbs were selected and randomly divided into a model group, a flurbiprofen group, a compound 33 group, a compound 2 group, a compound 13 group, a compound 20 group, and a compound 35 group according to the body weight, score and paw volume, and furthermore a blank control group was set up, with 8 rats in each group. The dosing volume was 10 mg/kg, and the dosing time was 14 days. A corresponding volume of solvent was administered in the model group and the blank control group.

[0310] Test indicators: body weight, arthritis score, hind limb paw volume, and mechanical foot threshold (MWT).

[0311] Standard for arthritis score: 0=normal; 1=erythema and slight swelling observed at the ankle joint; 2=erythema and slight swelling observed from the ankle joint to the metatarsal joint or the metacarpal joint; 3=erythema and moderate swelling observed from the ankle joint to the metatarsophalangeal joint or the metacarpal joint; 4=erythema and severe swelling observed from the ankle joint to the metatarsal joint; the total score of all (four) paws was calculated, and the sum of the arthritis indices was up to 16 per rat.

Test Results:

1. Effects of Test Drugs on Body Weight of Rats with CIA:

[0312] The results showed that there were no significant changes in the body weight of rats in each of groups during test, and the test drugs had no significant effect on the body weight of rats (MeanSD). The results were shown in FIG. 1.

2. Effects of Test Drugs on Arthritis Scores of Rats with CIA:

[0313] The results showed that the scores of rats in the model group were significantly higher than those of the rats in the blank control group during administration, and the arthritis scores of rats with CIA could be significantly reduced after 14-day intervention with each of test drugs (FIG. 2, P<0.01), indicating that the test drugs could significantly reduce the arthritis scores of rats with CIA.

3. Effects of Test Drugs on Hind Limb Paw Volume of Rats with CIA:

[0314] After 14-day intervention with each of the test drugs, all of the test drugs showed a significant effect of reducing the paw volume of the left hind limbs of rats with CIA (P<0.05 or 0.01). Compared with the model group, the paw volumes of the left lower limbs of rats with CIA were significantly reduced during the treatment with test drugs (FIG. 3). The groups of compound 33, compound 2, compound 13, compound 20, and compound 35 showed better effects as compared to the flurbiprofen group.

4. Effect of Test Drugs on Mechanical Withdrawal Threshold (MWT) of the Hind Limbs of Rats with CIA:

[0315] After successful modeling, the mechanical withdrawal threshold (MWT) of the left lower limbs of rats with CIA was significantly reduced as compared to the blank control group. After 13-day intervention and treatment with the test drugs, all the test drugs showed a significant effect of increasing MWT (FIG. 4, P<0.05), among which the groups of compound 33, compound 2, compound 13, compound 20, and compound 35 showed slightly better or better effects as compared to the flurbiprofen group.

Test Example 5: Antitumor Potency

[0316] Experimental method: The antitumor potency was tested by the MTT method. Tumor cells at the logarithmic phase were collected. The concentration of the cell suspension was adjusted. 100 L of the cell suspension was added to each well. Cell plating was carried out and the cell density was adjusted to 1000 to 10000/well (the marginal wells were filled with sterile PBS). The cells were incubated at 5% CO.sub.2 and 37 C. until the cells adhered to the wall (96-well flat-bottomed plate). Drugs of different concentration gradients were added, 100 L per well. Four replicates were set up. Under the conditions of 5% CO.sub.2 and 37 C., the cells were incubated for 72 h and observed under an inverted microscope. The prepared MTT solution (5 mg/mL) was added to the 96-well plate, 20 L per well, mixed well, and incubated for 4 h under the conditions of 37 C. and 5% CO.sub.2. Afterwards, the liquid in the plate was discarded. 150 L of DMSO was added to each well and oscillated for 3 min on a microplate reader. The OD value (optical density) was detected at 490 nm.

[0317] The inhibition rate of the drug against the tumor cell growth was calculated according to the following formula:

[00001]$\mathrm{cell}\mathrm{viability}\left(\%\right)=\left(\mathrm{OD}\mathrm{value}\mathrm{in}\mathrm{the}\mathrm{treatment}\mathrm{group}/\mathrm{OD}\mathrm{value}\mathrm{in}\mathrm{the}\mathrm{control}\mathrm{group}\right)100\%$

Experimental Results:

TABLE-US-00004 TABLE 4 Antitumor Test Results (IC.sub.50 value, unit: m) Tumor Cells Eca-109 MM.1S NUGC-4 U87 U251 H460 Flurbiprofen 85.54 >100 >100 >100 34.12 >100 Compound 33 >100 >100 >100 >100 >100 >100 Compound 2 55.73 41.70 59.96 >100 >100 90.03 Compound 13 30.69 5.39 40.10 80.46 73.86 47.94 Compound 20 33.18 42.75 50.43 54.63 5.84 35.89 Compound 35 29.62 45.73 41.78 60.31 7.33 32.58